Blar i forfatter "Amundsen, Tore"

Viser treff 1-2 av 2

    • Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma 

      Røe, Oluf Dimitri; Szulkin, Adam; Anderssen, Endre; Flatberg, Arnar; Sandeck, Helmut; Amundsen, Tore; Erlandsen, Sten Even; Dobra, Katalin; Sundstrøm, Stein Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2012)
      Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of malignant mesothelioma, but median survival is still one year. Intrinsic and acquired resistance to pemetrexed is common, but its biological basis is obscure. Here we report for the first time a genome-wide profile of acquired resistance in the tumour from an exceptional case with advanced pleural ...

    • Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group 

      Fløtten, Øystein; Grønberg, Bjørn Henning; Bremnes, Roy M.; Amundsen, Tore; Sundstrøm, Stein Harald; Rolke, Heidi; HORNSLIEN, KJERSTI; Wentzel-Larsen, Tore; Aasebø, Ulf; von Plessen, Christian (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-07-03)
      BACKGROUND: Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective and better tolerated. We conducted a national, randomised study to compare a non-platinum with a platinum combination.<p> <p>METHODS: Eligible patients had stage IIIB/IV NSCLC ...